AN2 Therapeutics Extends GSK Tuberculosis Research Collaboration
MENLO PARK, Calif. — September 28, 2026 AN2 Therapeutics, Inc. announced that the Gates Foundation has extended funding supporting...
Global Health
Advertisement
Ophirex Publishes Phase 2 BRAVIO Varespladib Data
Durham, North Carolina — September 22, 2026 Ophirex announced publication of results from the Phase 2 BRAVIO clinical trial...
Co-Diagnostics Joins WHO Consultation on Global Diagnostics
Salt Lake City, Utah, U.S., September 17, 2026 Co-Diagnostics, Inc., a molecular diagnostics company developing technologies for infectious disease...
BeOne Medicines Expands BRUKINSA Access for CLL Patients
SAN CARLOS, Calif. & SEATTLE, Aug. 18, 2026 BeOne Medicines Ltd., together with the BeOne Care Foundation and The...
GHIT Fund Accelerates Portable Ebola Diagnostic Innovation
TOKYO, Japan, July 23, 2026 The Global Health Innovative Technology (GHIT) Fund has announced an investment of approximately JPY...
Advertisements
Akagera Medicines Reports Positive Phase 1 AKG-100 Results
KIGALI, Rwanda, July 20, 2026 Akagera Medicines, Inc. has announced positive first-in-human Phase 1 results for AKG-100, its investigational...
PleoPharma Launches Phase 3 Trial for Cannabis Withdrawal
PHOENIXVILLE, Pa., June 20, 2026 PleoPharma, Inc. has announced the dosing of the first patient in CAN-004, its pivotal...
New Gates Foundation Grant Fuels Replicate’s Fight Against Tuberculosis
SAN DIEGO, Calif., June 20, 2026 Replicate Bioscience has secured a $3 million research grant from the Gates Foundation...
RedHill Advances Opaganib as Potential Ebola Treatment Amid Rare Bundibugyo Virus Outbreak
TEL AVIV, Israel and RALEIGH, N.C., June 2, 2026 RedHill Biopharma has announced efforts to advance the clinical development...
Soligenix Advances Bundibugyo Ebola Vaccine Platform
PRINCETON, New Jersey, May 26, 2026 Soligenix, Inc. has announced that its proprietary ThermoVax® vaccine platform may provide a...
Advertisement
